THERMO FISHER SCIENTIFIC INC.

TMO 10-K · FY 2025
API behind this page

TMO FY 2025 request

Playground key active
Request URL /api/financials?ticker=TMO&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue 44,556 42,879 +3.9%
Show Product Lines breakouts
Consumables 18,664 17,587 +6.1%
Instruments 7,301 7,446 -1.9%
Product 25,965 25,034 +3.7%
Service 18,592 17,845 +4.2%
Show Business Segments breakouts
Analytical Instruments 7,353 7,267 +1.2%
Analytical Instruments · Chemical analysis 1,237 1,315 -5.9%
Analytical Instruments · Chromatography and mass spectrometry 3,360 3,278 +2.5%
Analytical Instruments · Electron microscopy 2,957 2,870 +3.0%
Analytical Instruments · Material Reconciling Items 201 196 +2.6%
Analytical Instruments · Operating Segments 7,554 7,463 +1.2%
Laboratory Products and Biopharma Services 23,818 23,002 +3.5%
Laboratory Products and Biopharma Services · Clinical research 7,915 7,836 +1.0%
Laboratory Products and Biopharma Services · Intersubsegment Eliminations -920 -907 -1.4%
Laboratory Products and Biopharma Services · Laboratory products 2,407 2,525 -4.7%
Laboratory Products and Biopharma Services · Material Reconciling Items 167 155 +7.7%
Laboratory Products and Biopharma Services · Operating Segments 23,984 23,157 +3.6%
Laboratory Products and Biopharma Services · Pharma services 7,142 6,685 +6.8%
Laboratory Products and Biopharma Services · Research and safety market channel 7,440 7,019 +6.0%
Life Sciences Solutions 8,781 8,160 +7.6%
Life Sciences Solutions · BioProduction 3,200 2,652 +20.7%
Life Sciences Solutions · Biosciences 4,169 4,192 -0.5%
Life Sciences Solutions · Genetic sciences 2,870 2,787 +3.0%
Life Sciences Solutions · Material Reconciling Items 1,593 1,471 +8.3%
Life Sciences Solutions · Operating Segments 10,374 9,631 +7.7%
Life Sciences Solutions · Other 136 — —
Specialty Diagnostics 4,604 4,449 +3.5%
Specialty Diagnostics · Clinical diagnostics 1,115 1,063 +4.9%
Specialty Diagnostics · Healthcare market channel 1,788 1,764 +1.4%
Specialty Diagnostics · ImmunoDiagnostics 912 864 +5.6%
Specialty Diagnostics · Intersubsegment Eliminations -275 -266 -3.4%
Specialty Diagnostics · Material Reconciling Items 72 63 +14.3%
Specialty Diagnostics · Microbiology 645 633 +1.9%
Specialty Diagnostics · Operating Segments 4,676 4,512 +3.6%
Specialty Diagnostics · Transplant diagnostics 492 454 +8.4%
Show Geography breakouts
Asia Pacific 8,101 7,956 +1.8%
Europe 11,826 10,857 +8.9%
Non Us 22,316 21,124 +5.6%
North America 23,033 22,504 +2.4%
Other regions 1,597 1,561 +2.3%
US 22,240 21,755 +2.2%
Show Consolidation Items breakouts
Intersegment Elimination -2,033 -1,885 -7.9%
Material Reconciling Items 2,033 1,885 +7.9%
Operating Segments 46,589 44,764 +4.1%
Cost of Revenue (FY) — — —
Show Product Lines breakouts
Product 13,405 12,523 +7.0%
Service 12,913 12,654 +2.0%
Selling, General & Administrative 8,732 8,595 +1.6%
Show Business Segments breakouts
Analytical Instruments · Operating Segments 1,244 1,250 -0.5%
Laboratory Products and Biopharma Services · Operating Segments 2,392 2,356 +1.5%
Life Sciences Solutions · Operating Segments 1,912 1,797 +6.4%
Specialty Diagnostics · Operating Segments 708 732 -3.3%
Research & Development 1,397 1,390 +0.5%
Show Business Segments breakouts
Analytical Instruments · Operating Segments 573 551 +4.0%
Laboratory Products and Biopharma Services · Operating Segments 56 66 -15.2%
Life Sciences Solutions · Operating Segments 553 551 +0.4%
Specialty Diagnostics · Operating Segments 178 176 +1.1%
Restructuring And Other Costs Income Net 362 379 -4.5%
Show Business Segments breakouts
Analytical Instruments · Operating Segments 81 4 +1925.0%
Laboratory Products and Biopharma Services · Operating Segments 147 280 -47.5%
Life Sciences Solutions · Operating Segments 154 69 +123.2%
Specialty Diagnostics · Operating Segments 10 17 -41.2%
Show Consolidation Items breakouts
Corporate Non Segment -29 9 -422.2%
Material Reconciling Items 362 379 -4.5%
Total Costs & Expenses 36,810 35,542 +3.6%
Operating Income 7,746 7,337 +5.6%
Show Business Segments breakouts
Analytical Instruments · Operating Segments 1,736 1,955 -11.2%
Laboratory Products and Biopharma Services · Operating Segments 3,350 3,090 +8.4%
Life Sciences Solutions · Operating Segments 3,768 3,503 +7.6%
Specialty Diagnostics · Operating Segments 1,256 1,159 +8.4%
Show Consolidation Items breakouts
Operating Segments 10,109 9,707 +4.1%
Interest Income 993 1,078 -7.9%
Show Consolidation Items breakouts
Material Reconciling Items 993 1,078 -7.9%
Interest Expense -1,419 -1,390 -2.1%
Show Consolidation Items breakouts
Material Reconciling Items -1,419 -1,390 -2.1%
Other Non-Operating Income (Expense) -12 12 -200.0%
Show Consolidation Items breakouts
Material Reconciling Items -12 12 -200.0%
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments 7,308 7,037 +3.9%
Income Tax Expense (Benefit) -547 -657 +16.7%
Income Loss From Equity Method Investments -41 -42 +2.4%
Net Income 6,721 6,338 +6.0%
Net Income Loss Attributable To Noncontrolling Interest 17 3 +466.7%
Net Income 6,704 6,335 +5.8%
EPS (Basic) 17.77 16.58 +7.2%
EPS (Diluted) 17.74 16.53 +7.3%
Wtd Avg Shares (Basic) 377 382 -1.3%
Wtd Avg Shares (Diluted) 378 383 -1.3%
Cost of Revenue (FY) — — —
Show Business Segments breakouts
Analytical Instruments · Operating Segments 3,850 3,532 +9.0%
Laboratory Products and Biopharma Services · Operating Segments 18,609 18,020 +3.3%
Life Sciences Solutions · Operating Segments 3,929 3,560 +10.4%
Specialty Diagnostics · Operating Segments 2,718 2,605 +4.3%
Comprehensive Income 6,953 6,862 +1.3%
Foreign Currency Transaction Gain Loss Before Tax -130 0 —
Gain Loss On Investments 13 21 -38.1%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents 9,852 4,009 +145.7%
Short-Term Investments 253 1,561 -83.8%
Accounts Receivable 8,900 8,191 +8.7%
Inventory 5,425 4,978 +9.0%
Contract With Customer Asset Net Current 1,666 1,435 +16.1%
Other Assets Current 2,612 1,964 +33.0%
Total Current Assets 28,707 22,137 +29.7%
Non-Current Assets
Property, Plant & Equipment 10,565 9,306 +13.5%
Other Non-Current Assets 5,871 4,492 +30.7%
Goodwill 49,362 45,853 +7.7%
Show Business Segments breakouts
Analytical Instruments 5,143 4,959 +3.7%
Laboratory Products and Biopharma Services 24,232 23,773 +1.9%
Life Sciences Solutions 14,910 12,336 +20.9%
Specialty Diagnostics 5,076 4,784 +6.1%
Total Assets 110,343 97,321 +13.4%
Show Business Segments breakouts
Analytical Instruments · Operating Segments 3,170 2,944 +7.7%
Laboratory Products and Biopharma Services · Operating Segments 6,485 6,145 +5.5%
Life Sciences Solutions · Operating Segments 3,446 2,982 +15.6%
Specialty Diagnostics · Operating Segments 1,323 1,218 +8.6%
Show Consolidation Items breakouts
Material Reconciling Items 95,919 84,031 +14.1%
Operating Lease Right-of-Use Assets 1,447 1,489 -2.8%
Intangible Assets 14,604 14,298 +2.1%
Show Finite Lived Intangible Assets By Major Class breakouts
Customer Relationships 12,775 12,596 +1.4%
Developed Technology Rights 1,305 1,134 +15.1%
Order Or Production Backlog 37 41 -9.8%
Trade Names 486 527 -7.8%
Other Assets
Intangible Assets Net Excluding Goodwill 15,838 15,533 +2.0%
Current Liabilities
Debt Current 3,533 2,214 +59.6%
Accounts Payable 3,622 3,079 +17.6%
Employee Related Liabilities Current 1,995 1,988 +0.4%
Deferred Revenue (Current) 2,710 2,852 -5.0%
Other Liabilities Current 3,329 3,199 +4.1%
Total Current Liabilities 15,189 13,332 +13.9%
Non-Current Liabilities
Deferred Tax Liabilities 1,493 1,268 +17.7%
Other Non-Current Liabilities 4,273 3,989 +7.1%
Long-Term Debt 39,172 31,072 +26.1%
Show Long-Term Debt Type breakouts
Other 1 73 -98.6%
Senior Notes 39,171 30,999 +26.4%
Operating Lease Liabilities 1,195 1,239 -3.6%
Contract With Customer Liability Noncurrent 1,183 1,138 +4.0%
Other Liabilities
Long Term Debt And Capital Lease Obligations 35,852 29,061 +23.4%
Redeemable Noncontrolling Interest Equity Carrying Amount 122 120 +1.7%
Stockholders' Equity
Common Stock 445 444 +0.2%
Additional Paid In Capital Common Stock 18,563 17,962 +3.3%
Retained Earnings 59,156 53,102 +11.4%
Treasury Stock Common Value -22,309 -19,226 -16.0%
Accumulated Other Comprehensive Income -2,448 -2,697 +9.2%
Total Stockholders' Equity 53,407 49,584 +7.7%
Minority Interest 7 -33 +121.2%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 53,415 49,551 +7.8%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment -245 -263 +6.8%
Accumulated Gain Loss Net Cash Flow Hedge Parent -23 -25 +8.0%
Accumulated Other Comprehensive Income -2,448 -2,697 +9.2%
Accumulated Translation Adjustment -2,181 -2,409 +9.5%
Additional Paid In Capital 18,563 17,962 +3.3%
Common Stock 445 444 +0.2%
Noncontrolling Interest 7 -33 +121.2%
Parent 53,407 49,584 +7.7%
Retained Earnings 59,156 53,102 +11.4%
Treasury Stock Common -22,309 -19,226 -16.0%
Total Liabilities & Equity 110,343 97,321 +13.4%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Depreciation 1,050 1,156 -9.2%
Show Business Segments breakouts
Analytical Instruments · Operating Segments 104 103 +1.0%
Laboratory Products and Biopharma Services · Operating Segments 604 721 -16.2%
Life Sciences Solutions · Operating Segments 251 230 +9.1%
Specialty Diagnostics · Operating Segments 91 104 -12.5%
Amortization Of Intangible Assets 1,730 1,952 -11.4%
Show Consolidation Items breakouts
Material Reconciling Items 1,730 1,952 -11.4%
Deferred Income Taxes -639 -1,209 +47.1%
Stock-Based Compensation 310 301 +3.0%
Other Non-Cash Items 455 508 -10.4%
Change in Accounts Receivable -426 -171 -149.1%
Change in Inventory -74 -27 -174.1%
Increase Decrease In Contract With Customer Assets And Liabilities -375 -162 -131.5%
Change in Accounts Payable 421 212 +98.6%
Pension And Other Postretirement Benefit Contributions -42 -45 +6.7%
Increase Decrease In Other Operating Capital Net -1,312 -186 -605.4%
Net Cash from Operations 7,818 8,667 -9.8%
Investing Activities
Capital Expenditures -1,525 -1,400 -8.9%
Proceeds From Sale Of Property Plant And Equipment 44 57 -22.8%
Proceeds From Payments For Cross Currency Interest Rate Swap Interest Settlements 268 252 +6.3%
Payments To Acquire Businesses Net Of Cash Acquired -4,037 -3,132 -28.9%
Payments To Acquire Investments -383 -3,396 +88.7%
Proceeds From Sale Maturity And Collections Of Investments 1,565 1,770 -11.6%
Other Investing Activities 21 8 +162.5%
Net Cash from Investing -4,047 -5,841 +30.7%
Financing Activities
Proceeds From Issuance Of Long Term Debt 7,759 1,204 +544.4%
Repayments Of Long Term Debt -2,412 -3,607 +33.1%
Proceeds From Issuance Of Commercial Paper 1,095 — —
Repayments Of Commercial Paper -1,095 — —
Share Repurchases -3,000 -4,000 +25.0%
Payments Of Dividends Common Stock -636 -583 -9.1%
Proceeds From Payments For Other Financing Activities 90 195 -53.8%
Net Cash from Financing 1,801 -6,792 +126.5%
Supplemental
Income Taxes Paid 1,776 1,834 -3.2%
Interest Paid 1,612 1,570 +2.7%
Unpaid Capital Expenditures 264 303 -12.9%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 267 -91 +393.4%
Net Change in Cash 5,839 -4,057 +243.9%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 9,879 4,040 +144.5%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key